Compare Aon PLC (AON) vs Axogen Inc (AXGN) Price & Performance

AON trades at $356.97, down 0.37% with neutral technical signals. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $3.81 versus $3.80 expected, marking the third consecutive quarterly beat. Revenue growth accelerated to 5% organic in Q2 2026, while margins expanded 70 basis points. Analyst consensus price target stands at $410, representing 15% upside potential from current levels.

AON presents a compelling investment case with consistent earnings outperformance and robust profitability metrics including 44.88% ROE. However, premium valuation multiples and modest organic growth create headwinds. The stock offers 15% upside to consensus targets but requires monitoring of valuation compression risks amid competitive insurance brokerage markets.

AXGN trades at $48.53, up 0.64% today, with a bullish technical signal from moving averages and strong analyst support. Q2 2026 revenue grew 23.1% to $69.7M, beating estimates, and full-year guidance was raised to at least $279M. However, the company remains unprofitable with a net income margin of -13.36% and negative ROE, reflecting high SG&A costs relative to revenue.

The outlook is mixed: robust revenue growth and FDA-backed nerve care platform expansion offer upside, but persistent losses and high valuation multiples (P/S 9.57) pose risks. With 84% analyst buy ratings and a $54.33 price target, near-term momentum depends on execution toward profitability amid competitive and reimbursement pressures.